These products can raise NAD-related blood measures, but broad clinical benefits remain uncertain
Understanding these predispositions can support a more informed conversation with your provider about whether GLP-1 therapy aligns with your biological profile, independent of Medicaid coverage decisions
In previous large-scale clinical trials of GLP-1RAs, 15.2% ( n = 618) of AMPLITUDE-O and 6.1% ( n = 575) of Harmony Outcomes patients used SGLT2is at baseline [18, 20] (Table 1)
doi: 10.1080/15548627.2021.1962682 96 GyeongmiKSe-KyeongJYu JinKHyeon-OkJSeungheeBJungilHet al
FDA concluded that based on the available evidence, that the supply of semaglutide meets or exceeds current demand, and that, based on our best judgment looking at the available information with its limitations, supply will meet or exceed projected demand. FDA acknowledges in the Declaratory Order that: [E]ven when a shortage is considered resolved, patients and prescribers may still see intermittent localized supply disruptions as products move through the supply chain from the manufacturer and distributors to local pharmacies
